BioMarin Pharmaceuticals Inc (BMRN) Stock Price

BMRNStock

$54.68+3.27%52W

Market Cap$10.58B

P/E30.34x

PEG Ratio0.32

Div yield—

Beta0.23

BMRN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-11.33%

Price vs S&P 500 (4W)-13.32%

PEG Ratio0.32

VGM Score51.95

P/E Ratio (Annual)30.34x

P/CF (Annual)12.78x

Book Value / Share (Quarterly)$32.66

P/TBV (Annual)1.98x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)15.40%

Cash Flow / Share (Quarterly)$3.75

Price vs S&P 500 (YTD)-19.92%

Gross Margin (TTM)79.62%

Net Profit Margin (TTM)2.14%

EPS (TTM)$0.36

10-Day Avg Trading Volume2.59M

EPS Excl Extra (TTM)$0.36

Revenue Growth (5Y)11.60%

EPS (Annual)$1.77

ROI (Annual)5.22%

Gross Margin (Annual)81.43%

Net Profit Margin (5Y Avg)7.20%

Cash / Share (Quarterly)$4.52

P/E Basic Excl Extra (TTM)145.05x

Revenue Growth QoQ (YoY)19.91%

EPS Growth (5Y)-16.98%

P/E Normalized (Annual)30.34x

ROA (Last FY)4.59%

Revenue Growth TTM (YoY)11.20%

EBITD / Share (TTM)$1.22

ROE (5Y Avg)3.65%

Operating Margin (TTM)4.38%

Cash Flow / Share (Annual)$3.73

P/B Ratio1.67x

P/B Ratio (Quarterly)1.75x

Net Income / Employee (Annual)$108,300

EV / Revenue (TTM)4.08x

Net Interest Coverage (TTM)-21.18x

ROA (TTM)0.82%

EPS Growth QoQ (YoY)-81.14%

EV / EBITDA (TTM)58.65x

EPS Incl Extra (Annual)$1.77

Current Ratio (Annual)5.21x

Quick Ratio (Quarterly)1.16x

3-Month Avg Trading Volume2.04M

52-Week Price Return3.27%

EV / Free Cash Flow (Annual)19.38x

P/E Incl Extra (TTM)145.05x

Revenue / Employee (TTM)$1,057,600

Tangible BV / Share (Quarterly)$7.45

P/S Ratio (Annual)3.29x

Asset Turnover (Annual)0.42x

52-Week High$70.98

Operating Margin (5Y Avg)8.01%

EPS Excl Extra (Annual)$1.77

CapEx CAGR (5Y)-4.20%

Tangible BV CAGR (5Y)9.35%

26-Week Price Return-1.42%

Quick Ratio (Annual)3.50x

13-Week Price Return-8.24%

Total Debt / Equity (Annual)0.10x

Current Ratio (Quarterly)2.39x

Enterprise Value$13.90B

Revenue / Share Growth (5Y)10.95%

Asset Turnover (TTM)0.38x

Book Value / Share Growth (5Y)6.97%

Revenue / Employee (Annual)$1,000,100

Inventory Turnover (Annual)0.47x

Pretax Margin (Annual)14.98%

Cash / Share (Annual)$8.12

3-Month Return Std Dev30.34%

Gross Margin (5Y Avg)78.11%

Net Income / Employee (TTM)$22,700

EBITDA CAGR (5Y)75.99%

EBITDA Interim CAGR (5Y)46.64%

ROE (Last FY)5.73%

Net Interest Coverage (Annual)2.16x

EPS Basic Excl Extra (Annual)$1.77

P/FCF (TTM)14.60x

Receivables Turnover (TTM)3.55x

EV / Free Cash Flow (TTM)19.17x

Total Debt / Equity (Quarterly)0.66x

EPS Incl Extra (TTM)$0.36

Receivables Turnover (Annual)4.11x

ROI (TTM)0.93%

P/S Ratio (TTM)3.11x

Pretax Margin (5Y Avg)8.96%

Revenue / Share (Annual)$16.32

Tangible BV / Share (Annual)$29.99

Forward P/E15.64x

Price vs S&P 500 (52W)-12.26%

P/E Ratio (TTM)145.05x

EPS Growth TTM (YoY)-89.17%

Year-to-Date Return-7.99%

5-Day Price Return-1.28%

EPS Normalized (Annual)$1.77

ROA (5Y Avg)2.86%

Net Profit Margin (Annual)10.83%

Month-to-Date Return-8.87%

Cash Flow / Share (TTM)$1.30

EBITD / Share (Annual)$2.17

EPS Growth (3Y)33.12%

Operating Margin (Annual)12.71%

LT Debt / Equity (Annual)0.10x

P/CF (TTM)12.35x

ROI (5Y Avg)3.22%

P/E Excl Extra (TTM)145.05x

LT Debt / Equity (Quarterly)0.56x

EPS Basic Excl Extra (TTM)$0.36

P/TBV (Quarterly)7.67x

P/B Ratio (Annual)1.88x

Inventory Turnover (TTM)0.41x

Pretax Margin (TTM)4.38%

Book Value / Share (Annual)$31.65

Price vs S&P 500 (13W)-10.93%

Net Margin Growth (5Y)-25.18%

Beta0.23x

P/FCF (Annual)14.76x

Revenue / Share (TTM)$17.52

ROE (TTM)1.18%

52-Week Low$49.26

vGradeC

gGradeC

mGradeB

vgmGradeC

BMRN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	$0.95	$1.20	+25.75%(+$0.25)
Q1 2026	May 4, 2026	$0.91	$0.76	-16.86%(-$0.15)
Q4 2025	Feb 23, 2026	$0.56	$0.46	-17.94%(-$0.10)
Q3 2025	Oct 27, 2025	$0.34	$0.12	-64.34%(-$0.22)
Q2 2025	Aug 4, 2025	$1.03	$1.44	+39.40%(+$0.41)

BMRN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.12

4.09

4.06

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About BioMarin Pharmaceuticals Inc

BioMarin Pharmaceutical develops therapies for rare genetic diseases, specializing in enzyme replacement and gene therapies. The company has eight approved treatments for achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. An early-stage pipeline targets additional skeletal conditions and enzyme-based therapies.

BMRN Next Earnings Report

Report dateOct 26, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$0.95

Revenue estimate$1.03B

Also reporting on Oct 26, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for October 2026

BMRN Insider Transactions

SellSep 2, 2026
DAVIS GEORGE ERIC
Officer
Shares: 17,557Value: $1.16M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

RPMRPM International, Inc.Paints & Coatings
TECHBio-Techne Corp.Biological Products
ALBAlbemarle CorporationPlastics & Resins
RGENRepligen CorpBiological Products
CLXClorox CompanyCleaning & Polishing Products
APGEApogee Therapeutics, Inc. Common StockBiological Products
PCVXVaxcyte, Inc. Common StockBiological Products
IBRXImmunityBio, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$49.26

High$70.98